Counselors in Shenandoah, IA Accepting Medicare
6 Counselors found. Showing 1 - 6
 Susan K Narduccie, LMHP Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 600 Fremont St, Shenandoah, IA 51601 Phone: 712-246-5506 Fax: 712-246-5506 |
Michelle Marie Jarosz, LMHC Counselor - Mental Health Medicare: Medicare Enrolled Practice Location: 523 W Sheridan Ave, Shenandoah, IA 51601 Phone: 712-246-0159 Fax: 712-246-2879 |
Kindra A Weston Counselor - Mental Health Medicare: Medicare Enrolled Practice Location: 300 Park Ave, Shenandoah, IA 51601 Phone: 712-246-7390 Fax: 712-246-7319 |
Mrs. Melissa Marie Hobbie, LMSW Counselor - Mental Health Medicare: Accepting Medicare Assignments Practice Location: 1 Jack Foster Dr, Shenandoah, IA 51601 Phone: 712-246-7423 |
Edanne Lynn Murphy Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 509 W Sheridan Ave, Shenandoah, IA 51601 Phone: 712-520-0237 Fax: 866-675-5954 |
Angela Dawn Mace Counselor - Mental Health Medicare: Medicare Enrolled Practice Location: 523 W Sheridan Ave, Shenandoah, IA 51601 Phone: 712-246-0159 Fax: 712-246-2879 |
News Archive
Almac Discovery initiates Phase I clinical trial of intranasal Granisetron for CINV
Almac Discovery today announced the start of Phase I clinical trial of the novel intranasal Granisetron product. This product, which uses Archimedes' proprietary ChiSys® delivery technology, is being developed as a rapidly acting, well tolerated and convenient treatment for chemotherapy-induced nausea and vomiting (CINV).
High expression of interleukin-9 in immune cells inhibits melanoma growth
Researchers from Brigham and Women's Hospital (BWH) have made a groundbreaking discovery that will shape the future of melanoma therapy. The team, led by Thomas S. Kupper, MD, chair of the BWH Department of Dermatology, and Rahul Purwar, PhD, found that high expression of a cell-signaling molecule, known as interleukin-9, in immune cells inhibits melanoma growth.
New self-expanding bioprosthetic valve used in TAVR fails to demonstrate non-inferiority
In a randomized clinical trial, SCOPE II, a new self-expanding bioprosthetic valve used in transcatheter aortic valve replacement (TAVR) failed to demonstrate non-inferiority compared to an existing self-expanding valve.
Taiho Pharmaceutical announces early stage data for eight novel oncology compounds
Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.
› Verified 8 days ago
Pharmacists
Dentists
Counselors
Occupational Therapists
Clinical Social Workers